This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Facial Plastic Surgery  • Biomaterials and Implants  • Alert me on articles by topic  Social Bookmarking   What's this?

Arthur O. Tzianabos, PhD; Ronald L. Cisneros, MS; Julia Gershkovich, MS; Jeff Johnson, MS; Robert J. Miller, PhD; James W. Burns, PhD; Andrew B. Onderdonk, PhD

Arch Surg. 1999;134:1254-1259.

Hypothesis  The use of certain surgical adhesion reduction devices where there is a risk of concomitant bacterial contamination potentiates intra-abdominal infection.

Design  Evaluation of adhesion reduction devices in an experimental model of intra-abdominal infection.

Setting  Experimental animal model.

Interventions  Adhesion reduction devices were administered at the time of bacterial challenge.

Main Outcome Measures  Animal mortality rate, abscess formation, and bacterial counts in peritoneal fluid and blood cultures.

Results  The use of bioresorbable membrane adhesion reduction devices in the presence or absence of antibiotic therapy did not alter the disease process as compared with appropriate control groups. However, adhesion reduction gels prepared from sodium hyaluronate and carboxymethylcellulose chemically modified with carbodiimide or ferric ion complexed sodium hyaluronate increased the incidence of peritonitis in treated animals. Gel formulations containing diimide-modified carboxymethylcellulose did not have this effect.

Conclusions  The use of certain adhesion reduction devices resulted in the propagation of intra-abdominal infection in an experimental rat model. This outcome was dependent on the composition of the device employed. The use of adhesion reduction devices should be tested in appropriate models of infection where there is the risk of concomitant bacterial contamination.

From Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Drs Tzianabos and Onderdonk and Mr Cisneros); and Genzyme Corp, Cambridge, Mass (Drs Miller and Burns, Ms Gershkovich, and Mr Johnson). Dr Tzianabos and Dr Onderdonk do not hold an equity position in Genzyme Corp, but do serve as consultants. Ms Gershkovich, Mr Johnson, and Drs Miller and Burns are all employees of Genzyme Corp.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Surface Treatment of Flexor Tendon Autografts with Carbodiimide-Derivatized Hyaluronic Acid. An in Vivo Canine Model
Zhao et al.
JBJS 2006;88:2181-2191.
ABSTRACT | FULL TEXT  

Seprafilm May Ease Colostomy Reversal
Saribeyoglu et al.
Arch Surg 2004;139:1380-1382.
ABSTRACT | FULL TEXT  

Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway
Holsti et al.
J. Immunol. 2004;172:5774-5781.
ABSTRACT | FULL TEXT  

Protective effect of ethyl-3-(3-dimethyl aminopropyl)urea dihydrochloride (EDU) against LPS-induced death in mice
Matsumoto et al.
J Med Microbiol 2004;53:97-102.
ABSTRACT | FULL TEXT  

Effect of Intraperitoneal Antiadhesive Fluids in a Rat Peritonitis Model
Muller et al.
Arch Surg 2003;138:286-290.
ABSTRACT | FULL TEXT